Significant impact of IL-6-174G/C but inverse relation with-634 C/G polymorphism in patients with non-small cell lung cancer in kashmiri population

Immunological Investigations

Volumn 44, Issue 4, 2015, Pages 349-360

  Bhat, Imtiyaz A ^a   Qasim, Iqbal ^a   Masoodi, Khalid Z ^b   Paul, Shabeer A ^a   Bhat, Bashir A ^a   Rasool, Roohi ^a   Aziz, S A ^a   Shah, Zafar A ^a  

^a SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

^b SHER E KASHMIR UNIVERSITY OF AGRICULTURAL SCIENCES AND TECHNOLOGY OF KASHMIR   (India)

Author keywords

Inflammation; Non small cell lung cancer; Polymorphism; Restriction fragment length polymorphism (RFLP)

Indexed keywords

INTERLEUKIN 6; RESTRICTION ENDONUCLEASE; TAQ POLYMERASE;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KASHMIRI (PEOPLE); MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PATHOGENESIS; POLYMERASE CHAIN REACTION; POPULATION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; AGED; ALLELE; CANCER GRADING; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; ODDS RATIO; PATHOLOGY;

ADULT; AGED; ALLELES; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA;

EID: 84928890221     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2015.1004336     Document Type: Article

References (59)

1. Aggarwal BB, Shishodia S, Sandur SK, et al. (2006). Inflammation and cancer: how hot is the link? Biochem Pharmacol, 72, 1605-21
2. Apostolou P, Tsantsaridou A, Papasotiriou I, et al. (2011). Bacterial and fungal microflora in surgically removed lung cancer samples. J Cardiothor Surg, 6, 137
3. Bennermo M, Held C, Stemme S, et al. (2004). Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases? Clin Chem, 50, 2136-40
4. Berek JS, Chung C, Kaldi K, et al. (1991). Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol, 164, 1038-42; discussion 1042-3
5. Brenner DR, Boffetta P, Duell EJ, et al. (2012). Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. Am J Epidemiol, 176, 573-85
6. Campa D, Zienolddiny S, Maggini V, et al. (2004). Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis, 25, 229-35
7. Chang SH, Mirabolfathinejad SG, Katta H, et al. (2014). T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci USA, 111, 5664-9
8. Chen Z, Malhotra PS, Thomas GR, et al. (1999). Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res, 5, 1369-79
9. Coussens LM, Werb Z. (2002). Inflammation and cancer. Nature, 420, 860-7
10. Cummins J, Tangney M. (2013). Bacteria and tumours: causative agents or opportunistic inhabitants? Infect Agent Cancer, 8, 11
11. Dela Cruz CS, Tanoue LT, Matthay RA. (2011). Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med, 32, 605-44
12. Duan Z, Feller AJ, Penson RT, et al. (1999). Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxelresistant phenotype. Clin Cancer Res, 5, 3445-53
13. Duan Z, Lamendola DE, Penson RT, et al. (2002). Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine, 17, 234-42
14. Fernandez-Real JM, Broch M, Vendrell J, et al. (2000). Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab, 85, 1334-9
15. Ganesh B, Sushama S, Monika S, Suvarna P. (2011). A case-control study of risk factors for lung cancer in Mumbai, India. Asian Pac J Cancer Prev, 12, 357-62
16. Guo Y, Xu F, Lu T, et al. (2012). Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev, 38, 904-10
17. Haddy N, Sass C, Maumus S, et al. (2005). Biological variations, genetic polymorphisms and familial resemblance of TNF-Alpha and IL-6 concentrations: STANISLAS cohort. Eur J Hum Genet, 13, 109-17
18. He JQ, Foreman MG, Shumansky K, et al. (2009). Associations of IL6 polymorphisms with lung function decline and COPD. Thorax, 64, 698-704
19. Hong DS, Angelo LS, Kurzrock R. (2007). Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer, 110, 1911-28
20. Jackson LA, Wang SP, Nazar-Stewart V, et al. (2000). Association of Chlamydia pneumoniae immunoglobulin A seropositivity and risk of lung cancer. Cancer Epidemiol Biomarkers Prev, 9, 1263-6
21. Ju R, Wu D, Guo L, et al. (2012). Inhibition of pro-inflammatory cytokines in tumour associated macrophages is a potential anti-cancer mechanism of carboxyamidotriazole. Eur J Cancer, 48, 1085-95
22. Karin M. (2006). Nuclear factor-kappaB in cancer development and progression. Nature, 441, 431-6
23. Karin M, Greten FR. (2005). NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol, 5, 749-59
24. Kitamura A, Hasegawa G, Obayashi H, et al. (2002). Interleukin-6 polymorphism (-634C/G) in the promotor region and the progression of diabetic nephropathy in type 2 diabetes. Diabet Med, 19, 1000-5
25. Lim CS, Zheng S, Kim YS, et al. (2002). The-174 G to C polymorphism of interleukin-6 gene is very rare in koreans. Cytokine, 19, 52-4
26. Lim WY, Chen Y, Ali SM, et al. (2011). Polymorphisms in inflammatory pathway genes, host factors and lung cancer risk in Chinese female never-smokers. Carcinogenesis, 32, 522-9
27. Lu C, Sheehan C, Rak JW, et al. (1996). Endogenous interleukin 6 can function as an in vivo growth-stimulatory factor for advanced-stage human melanoma cells. Clin Cancer Res, 2, 1417-25
28. Mantovani A. (2005). Cancer: inflammation by remote control. Nature, 435, 752-3
29. Margaglione M, Bossone A, Cappucci G, et al. (2001). The effect of the interleukin-6 c/g-174 polymorphism and circulating interleukin-6 on fibrinogen plasma levels. Haematologica, 86, 199-204
30. Mouawad R, Benhammouda A, Rixe O, et al. (1996). Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res, 2, 1405-9
31. Nakajima T, Ota N, Yoshida H, et al. (1999). Allelic variants in the interleukin-6 gene and essential hypertension in Japanese women. Genes Immun, 1, 115-9
32. Nandakumar A. (2001). Consolidated report of the population based cancer registries, incidence &distribution of cancer, 1990-1996. New Delhi: Indian Council of Medical Research
33. Oberbach A, Lehmann S, Kirsch K, et al. (2008). Long-term exercise training decreases interleukin-6 (IL-6) serum levels in subjects with impaired glucose tolerance: effect of the-174G/C variant in IL-6 gene. Eur J Endocrinol, 159, 129-36
34. Oka M, Yamamoto K, Takahashi M, et al. (1996). Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res, 56, 2776-80
35. Pandith AA, Siddiqi MA. (2012). Burden of cancers in the valley of Kashmir: 5 year epidemiological study reveals a different scenario. Tumour Biol, 33, 1629-37
36. Peng WJ, He Q, Yang JX, et al. (2012). Meta-Analysis of association between cytokine gene polymorphisms and lung cancer risk. Mol Biol Rep, 39, 5187-94
37. Pu YS, Hour TC, Chuang SE, et al. (2004). Interleukin-6 is responsible for drug resistance and anti-Apoptotic effects in prostatic cancer cells. Prostate, 60, 120-9
38. Rauramaa R, Vaisanen SB, Luong LA, et al. (2000). Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol, 20, 2657-62
39. Rogers MB. (2011). Mycoplasma and cancer: in search of the link. Oncotarget, 2, 271-3
40. Ryu JH, Kim SJ. (2012). Interleukin-6-634 C/G and-174 G/C polymorphisms in Korean patients undergoing hemodialysis. Kor J Intern Med, 27, 327-37
41. Sanders J, Hawe E, Brull DJ, et al. (2009). Higher IL-6 levels but not IL6-174G4C or-572G4C genotype are associated with post-operative complication following coronary artery bypass graft (CABG) surgery. Atherosclerosis, 204, 196-201
42. Scambia G, Testa U, Benedetti Panici P, et al. (1995). Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer, 71, 354-6
43. Schwabe RF, Jobin C. (2013). The microbiome and cancer. Nat Rev Cancer, 13, 800-12
44. Seow A, Ng DP, Choo S, et al. (2006). Joint effect of asthma/atopy and an IL-6 gene polymorphism on lung cancer risk among lifetime non-smoking Chinese women. Carcinogenesis, 27, 1240-4
45. Shafia S, Afroze D, Sofi FA, et al. (2014). Rheumatoid arthritis and genetic variations in cytokine genes: a population-based study in Kashmir Valley. Immunol Invest, 43, 349-59
46. Shariat SF, Andrews B, Kattan MW, et al. (2001). Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology, 58, 1008-15
47. Srisuma S, Biswal SS, Mitzner WA, et al. (2003). Identification of genes promoting angiogenesis in mouse lung by transcriptional profiling. Am J Respir Cell Mol Biol, 29, 172-9
48. Terry CF, Loukaci V, Green FR. (2000). Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem, 275, 18138-44
49. Travis LB, Gospodarowicz M, Curtis RE, et al. (2002). Lung cancer following chemotherapy and radiotherapy for Hodgkins disease. J Natl Cancer Inst, 94, 182-92
50. Trikha M, Corringham R, Klein B, Rossi JF. (2003). Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res, 9, 4653-65
51. van den Borst B, Souren NY, Gielen M, et al. (2011). Association between the IL6-174G/ C SNP and maximally attained lung function. Thorax, 66, 179; author reply 179-80
52. Vickers MA, Green FR, Terry C, et al. (2002). Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res, 53, 1029-34
53. Wang Y, Niu XL, Qu Y, et al. (2010). Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett, 295, 110-23
54. Wani MA, Jan FA, Khan NA, et al. (2014). Cancer trends in Kashmir; common types, site incidence and demographic profiles: National Cancer Registry 2000-2012. Ind J Cancer, 51, 133-7
55. White ES, Strom SR, Wys NL, Arenberg DA. (2001). Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J Immunol, 166, 7549-55
56. Wu CW, Wang SR, Chao MF, et al. (1996). Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol, 91, 1417-22
57. Wypasek E, Undas A, Sniezek-Maciejewska M, et al. (2010). The increased plasma C-reactive protein and interleukin-6 levels in patients undergoing coronary artery bypass grafting surgery are associated with the interleukin-6-174G 4 C gene polymorphism. Ann Clin Biochem, 47, 343-9
58. Zhai R, Liu G, Yang C, et al. (2001). The G to C polymorphism at-174 of the interleukin-6 gene is rare in a Southern Chinese population. Pharmacogenetics, 11, 699-701
59. Zhang GJ, Adachi I. (1999). Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res, 19, 1427-32